Hot Longevity Mandate: US-Based Pharma

14 Sep

The firm is a multinational biopharmaceutical corporation. The firm develops and produces medicines, vaccines and consumer health care products. The firm looks to invest in/partner with academic research and start-up companies for developing innovative therapies and delivering value to the company. The firm has established a number of partnering models including Academic & Start-Up Company Partnerships, Alternative Development / Funding Models, Centers for Therapeutic Innovation, Global Scouting, Open Innovation Portal and a Corporate Venture Fund. The firm also takes part in equity rounds, usually with rights attached. The company is open to make co-development deals to help early-stage biotech companies, and is currently looking for new investment opportunities across the globe with a focus in North America, Europe, and Asia.c

The firm is currently looking for innovative therapeutics and medical technologies targeting the following areas: Cardiovascular & Metabolic Diseases, Immunology & Inflammation, Neuroscience, Oncology (including Immuno-Oncology), Rare Diseases (Gene Therapy as a platform), and Vaccines. In neuroscience, the firm is focused on neurodegenerative diseases, particularly technology in Alzheimer’s and Parkinson’s disease, and is open to preclinical (conception) to Ph III technology in this strategy. Neuroscience companies in neuroinflammation (i.e. microglia) and other emerging CNS areas, including CNS rare diseases and symptom-treating technology, require robust Ph II (or beyond) data. For rare indications, the firm requires a therapeutic approach that directly addresses the genetic cause of the disease. The firm is also open to other life science technologies that may speed up the development process, including lab technology and drug development enabling technologies. The firm also seeks in-licensing products for development. Overall, the firm is open to all stages of development, as the firm has separate teams to encompass all phases of development from preclinical to commercial stages.

The firm collaborates – in multiple formats – with both privately held and public life science companies with experienced management teams, innovative technologies, and an established scientific unit.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

What Makes a Great Banking Partner?

9 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

A question not asked enough by early-stage startup founders when looking for banking options is, “Which available resources are specific to the needs of my company and industry?” In a recent conversation with First Republic Bank’s Nishta Rao, we discussed this question, why it isn’t asked enough, and what founders stand to gain when they understand how much more valuable a banking relationship can be when it’s the right fit. We discuss First Republic’s life science toolkit and the resources available to early-stage startups in life science and healthcare.

Listen to our conversation and get to know First Republic Bank at RESI Partnering Week, September 13-15. Sign up today and mark your calendar for the sessions answering your questions about what a powerful banking relationship can do for you.  

Tuesday, September 14 | 11 AM EDT

Beyond Banking: Finding the Right Financial Partner for You

  • Nishta Rao, Managing Director, Life Science, First Republic Bank
  • Dennis Ford, CEO, Life Science Nation 

When your startup firm gains traction, you will inevitably need a bank that can add value and understand your distinct early-stage entrepreneurial needs. There are an array of financial institutions that have programs in the life science market to aid and guide early-stage entrepreneurs to set up the right financial packages. First Republic Bank is a leader in the early-stage life science market with decades of experience and dedicated teams that provide support to scientist entrepreneurs. In this fireside chat, we discuss the programs and services available for startups and how to engage and take advantage of the FRB offerings to help your business grow.

Wednesday, September 15 | 3 PM EDT

How to Evaluate Your Banking Partner Workshop

  • Nishta Rao, Managing Director, Life Science, First Republic Bank

Life Science companies need more from a bank than just accounts and transactions. The right banking partner brings a mix of excellent service, industry expertise, and the ability to help companies grow. Join Nishta Rao of First Republic Bank to hear what companies should be looking for in a sound banking partner.

RESI Partnering Week Final Agenda

9 Sep

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI Partnering Week, September 13-17, launches next week and featuring a star-studded lineup of panel discussions, live pitch sessions, educational workshops, fireside chats, and partnering. Check out our lineup of pre-recorded content, as well as the schedule of live events across Digital RESI September, RESI AI, and RESI Longevity.

If you haven’t yet signed up to start booking meetings and connecting with investors who are a fit for your product and stage of development, there is still time. Sign up today!

Digital RESI
(September 13-15)
  Monday (9/13) Tuesday (9/14) Wednesday (9/15)
9:00 EDT   Company Valuation for Fundraising Workshop  
10:00 EDT Medical Devices Panel Asia Cross-Border Panel Corporate VC Panel
11:00 EDT IPC Session 1: Therapeutics Beyond Banking: Finding the Right Financial Partner for You Negotiating Term Sheets Workshop
12:00 EDT Seed Funds Panel Tales from the Road Panel Angels & Family Offices Panel
13:00 EDT IPC Session 2: Diagnostics UCSF Innovation Ventures and Entrepreneurship Program Workshop Financing Scientific Instrumentation as a Startup Company Workshop
IPC Session 5: Oncology
14:00 EDT Big Pharma Panel Mental & Behavioral Health Panel IPC Session 8: R&D / Manufacturing Services
15:00 EDT IPC Session 3: Novel Drug Delivery Fundraising Bootcamp Workshop How to Evaluate Your Banking Partner Workshop
16:00 EDT IPC Session 4: Cardiovascular & Ophthalmic Disorders IPC Session 6: Medical Devices IPC Session 9: Therapeutics
17:00 EDT Why US Biotechs are Coming to Australia… Workshop IPC Session 7: Therapeutics IPC Session 10: Medical Devices & Digital Health
 
 
RESI AI & RESI Longevity
(September 16-17)
  Thursday (9/16) Friday (9/17)
10:00 EDT Healthcare Communications Panel Accelerated Pharma Development Panel
Social Isolation & Loneliness Panel Health & Homecare Panel
11:00 EDT   Commercialization of AI Technologies Workshop
Medical Accountability & Adherence Panel
12:00 EDT IPC Session 1: Therapeutics & Devices IPC Session 2: Digital Health and R&D/Manufacturing
Designing Innovation in Assisted Living and Aging in Place
13:00 EDT IPC Session 1: Medical Devices IPC Session 3: Digital Health
14:00 EDT   Diagnostic Wearables Panel
Funding and Strategic Directions with the National Institute on Aging Fireside Chat
15:00 EDT IPC Session 2: Diagnostics & Therapeutics What Angels, Seed, Venture, Corporate and Family Offices Investors Are Looking For Panel
16:00 EDT Healthcare Systems and Infrastructure Panel Precision Medicine Panel
Creating Better Dementia Care and Promoting Brain Health Panel
  Pre-Recorded Sessions
  Fundraising Bootcamp Workshop
  The Future of Wearables and Older Adults 2021
  Portfolio Spotlight with Mary Furlong & Associates (MFA)
  National Institute on Aging Seed Funding Overview and Portfolio Showcase
  Fundraising Bootcamp Workshop

700+ Investors at RESI Partnering Week

9 Sep

By Joey Wong, Investor Research Analyst, LSN

700+ investors representing VC, Corporate VC, Big Pharma, Angels, Family Offices, and more are meeting virtually across RESI Partnering Week, September 13-17. There is still time to sign up and start booking meetings. The RESI partnering platform is enabled to narrow down searches for investors who are a fit for your product, stage of development, and specific needs unique to your company. Check out the firms attending this week and select the conference you’re interested in to see the firms participating.

RPW Sept. 2021 Confirmed Investors
Confirmed RESI Investors Confirmed RESI AI Investors Confirmed RESI Longevity Investors
As of September 8
 
CI09082021

Hot Mandate: Corporate Venture Arm of Japan-based Big Pharma Invests in Therapeutics, Medical Devices and Digital Health Around the Globe

9 Sep

The corporate venture arm of a big pharma is a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare. The team is based in offices outside Boston, MA and Menlo Park, CA. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and is open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical devices and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Mandate: US-based VC Invests in Early-stage Companies Across All Sectors Life Sciences

9 Sep

A San Francisco based Venture Capital firm founded in 2016 is focused on early-stage healthcare companies. The firm currently has 29 companies in their portfolio, and has a network of family offices and high net worth individuals the firm shares deal flow with. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K in the form of equity or convertible notes. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US-focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication, and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. Bioverge prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Mandate: US-based Family Offices Interested Global Therapeutics, Medical Devices and Diagnostics Opportunities

9 Sep

The healthcare-focused arm of a family office based in Boca Raton, FL is interested in global companies but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs. Current portfolio companies include companies involved in cancer care, neurostimulation device, and cardiology device companies.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

← Older Entries
Newer Entries →